BMT CTN 1506 ("MORPHO"; NCT02997202) was a randomized phase 3 study of gilteritinib compared to placebo as maintenance therapy after hematopoietic stem cell transplantation (HCT) for patients with FLT3-ITD-mutated acute myeloid leukemia (AML). A key secondary endpoint was to determine the impact on survival of pre- and/or post-HCT measurable residual disease (MRD), as determined using a highly sensitive assay for FLT3-ITD mutations. Generally, gilteritinib maintenance therapy was associated with improved relapse-free survival (RFS) for participants with detectable peri-HCT MRD, whereas no benefit was evident for those lacking detectable MRD.
View Article and Find Full Text PDFBackground: Pose estimation (PE) has the promise to measure pediatric movement from a video recording. The purpose of this study was to quantify the accuracy of a PE model to detect arm and leg movements in 3-month-old infants with and without (TD, for typical development) complex congenital heart disease (CCHD).
Methods: Data from 12 3-month-old infants (N = 6 TD and N = 6 CCHD) were used to assess MediaPipe's full-body model.
The development of new building elements, such as concrete and mortar with sustainable materials, which produce a lower carbon footprint, is an achievable milestone in the short term. The need to reduce the environmental impact of the production of cement-based materials is of vital importance. This work focuses on the evaluation of the life-cycle assessment, production costs, mechanical performance, and durability of three mortars and three concrete mixtures in which mixed recycled aggregates (MRAs) and biomass bottom ash from olive waste (oBBA) were included to replace cement and aggregates.
View Article and Find Full Text PDF